Introduction {#Sec1}
============

Reported prevalence of vertebral fractures (VFs) among smokers and COPD patients is high (9--79% \[[@CR1]--[@CR7]\]) and, in the international ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) cohort, we previously reported that short-term incidence of VFs is high in smokers and former smokers with one or more prevalent VF \[[@CR8]\]. A recent review described an association between cardiovascular disease (CVD) and osteoporosis \[[@CR9]\] and suggested the potential benefits from routine bone assessment in patients with CVD. Associations between emphysema and osteoporosis or bone density have also reported \[[@CR4], [@CR10], [@CR11]\]. An association between emphysema and coronary artery calcification (CAC) has been reported in some studies \[[@CR12], [@CR13]\] but not in others \[[@CR14]--[@CR16]\].

Although CAC itself may be clinically asymptomatic, it is associated with coronary heart disease in patients without known CHD \[[@CR17]--[@CR19]\], cardiovascular disease \[[@CR20]\], cardiac events \[[@CR21]\], and mortality \[[@CR22]--[@CR24]\]. Also, in a population of (former) smokers (National Lung Screening Trial (USA)), CAC was associated with CHD death and all-cause mortality \[[@CR25]\]. Calcification in the coronary arteries is related to the underlying plaque burden, and calcifications in the coronary arteries, aortic arch, and carotid arteries are correlated (moderate to strong) \[[@CR26]\].

Chest CT scans are regularly performed to evaluate pulmonary disease and can be used to diagnose emphysema. Additionally, CT scans give the opportunity to evaluate the bone status (bone attenuation (BA) and VFs) and CAC (expressed in Agatston score).

Therefore, the aim of this study was to evaluate the associations between variables measured on chest CT scans in current or former smokers from the ECLIPSE cohort:The association between prevalent VFs and baseline Agatston scoreThe association between baseline Agatston score and prevalent VFsThe association between baseline Agatston score and incident VFs within 1 and 3 years

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

The ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study is a non-interventional multicenter study that was started to search underlying mechanisms of disease progression in subjects with COPD and to identify biomarkers that may serve as surrogate endpoints and measures of disease progression ([Clinicaltrials.gov](http://clinicaltrials.gov) identifier NCT00292552; GlaxoSmithKline study SCO104960).

Detailed inclusion and exclusion criteria were described elsewhere \[[@CR27]--[@CR29]\]. In brief, current or former smokers (40--75 years old) with moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II--IV) or without COPD, with a smoking history of at least 10 pack years, were included. Subjects with respiratory diseases other than COPD, patients with α1-antitrypsin deficiency, with known history of significant inflammatory disease other than COPD, with an exacerbation requiring treatment within 4 weeks prior to enrolment, or subjects who used oral glucocorticosteroids (GC) at baseline were excluded.

Measurements {#Sec4}
------------

Demographic and pulmonary information were collected as well as number of pack years and smoking status. Detailed information can be found elsewhere \[[@CR27]--[@CR29]\].

CT scans were performed at full inspiration (120 kV peak, 40 mAs, 1.00 or 1.25-mm volumetric acquisition, General Electric or Siemens), at baseline, 1-year, and 3-year follow-up. CT scanners were calibrated regularly using industry and institutional standards. Emphysema, VFs, BA, and Agatston score were measured on these CT scans.

Emphysema was measured as % low attenuation area (%LAA), as described by Coxson et al. \[[@CR30]\]. The presence of emphysema was defined by a cutoff value of \> 10%LAA \[[@CR30]\].

Sagittal reformats containing the spine were superposed to create simulated lateral X-ray images. VFs from T~1~ to L~1~ were semi-quantitatively and subsequently quantitatively (using SpineAnalyzer Morphometry software; Optasia Medical, Cheadle, UK \[[@CR31]--[@CR33]\]) assessed on the 3-year follow-up images. VFs were classified according to the method by Genant et al. as grade 1 (mild), grade 2 (moderate), or grade 3 (severe) \[[@CR34]\]. If VFs were diagnosed on the 3-year scan, the 1-year scan was morphometrically assessed. If VFs were diagnosed on the 1-year scan, the baseline scan was also evaluated. Incident VFs were defined as new (no VF to any grade of VF) or worsening VFs (increase in grade of VF) as previously described \[[@CR8]\].

BA was measured semi-automatically in cubic areas of approximately 275 mm^3^ (slightly varying due to different voxel sizes between scanners) centered in vertebrae T~4~--T~12~. Mean BA of vertebrae T~4~--T~12~ was expressed in Hounsfield units (HU). Vertebrae that were fractured (grade 1 or higher \[[@CR34]\]) or that showed other abnormalities were excluded from BA measurements.

Agatston score measurements are described in detail elsewhere \[[@CR15], [@CR35]\]. Areas of ≥ 1 mm^3^ with a threshold of ≥ 130 HU in the course of a coronary artery were considered CAC. Agatston score was calculated as the sum of weighted areas (depending on peak attenuation within the area) on axial slices. Three groups were made based on Agatston score at baseline: zero (0 Agatston units (AU)), medium (1--400 AU), or high Agatston score (\> 400 AU).

Main outcome measure {#Sec5}
--------------------

The main outcome measures werePrevalent Agatston score (main factor: prevalent VFs)Prevalent VFs (main factor: prevalent Agatston score)Incident VFs within 1 and 3 years (main factor: prevalent Agatston score)

Possible confounders that were considered included age; sex; BMI; smoking status (current/former); number of pack years; presence of COPD; emphysema (\> 10%LAA); and in case of incident VFs, prevalent VFs at baseline. Since associations between BA and Agatston score \[[@CR36]\] and between BA and fractures \[[@CR1], [@CR37]\] have been reported, BA was included as a potential confounder.

Statistics {#Sec6}
----------

Association between prevalent VFs and baseline Agatston score

A chi-square test was used to compare the proportion of patients with a prevalent VF between the Agatston score groups. Logistic regression models (SAS 9.3, SAS Institute, Cary, NC, USA; LOGISTIC procedure) were used to evaluate the association between prevalent VFs (no VF, or ≥ 1 VF) and Agatston score group (zero 0 AU, medium 1--400 AU, or high \> 400 AU). To compare medium vs zero Agatston score group, only subjects with medium or zero Agatston score were included in the analyses. To compare high vs zero Agatston score, only subjects with high or zero Agatston score were included.b)Association between baseline Agatston score and prevalent VFs

To evaluate the association between Agatston score and prevalent VFs, logistic regression models including all subjects were used.c)Association between Agatston score and incident VFs within 1 and 3 years

A chi-square test was used to compare the proportion of patients with an incident VF between the Agatston score groups. To evaluate the association between Agatston score and incident VFs, Cox proportional hazard models were used (PHREG procedure). When incident VFs were expressed in numbers of incident VFs (0, 1, or ≥ 2), a nominal regression model was used (LOGISTIC procedure).

### Confounders {#Sec7}

Age, sex, and presence of COPD were included in all multivariate models; other confounders were included in the multivariate model if they independently changed the beta-coefficient of the main exposure ((a) prevalent VFs; (b) Agatston score group; (c) incident VFs) by 5% or more, or previously reported associations indicated that they should be included.

Odds ratios (ORs) and hazard ratios (HRs) are given with 95% CI. Subjects with complete availability of VF assessment and Agatston score evaluation were selected. Only 1 subject (0.2%) had missing data and was excluded from further analyses.

Results {#Sec8}
=======

Out of a total of 2298 ECLIPSE subjects (327 subjects without and 1971 with COPD), there were 586 subjects (411 with and 175 without COPD) with Agatston score and VF assessment available (Table [1](#Tab1){ref-type="table"}) \[[@CR8]\]. Of the patients with a zero Agatston score, 20 (10.2%) had one or more prevalent VFs, compared to 61 (22.9%) in the medium Agatston score group and 42 (33.9%) in the high Agatston score group (Fig. [1](#Fig1){ref-type="fig"}). The proportion of patients with a prevalent VF was significantly different across the Agatston score groups (*p* value \< 0.001). Of the patients with a zero Agatston score, 40 (20.4%) had one or more incident VFs within 3 years, compared to 60 (22.6%) in the medium Agatston score group and 37 (29.8%) in the high Agatston score group. The proportion of patients with an incident VF over 3 years increased (but not significantly) across the Agatston score groups (*p* value 0.14).Table 1Baseline characteristicsAll subjectsZero Agatston groupMedium Agatston groupHigh Agatston group*n* = 586*n* = 196*n* = 266*n* = 124Age (years: mean, sd)59.88.355.07.660.87.765.36.1Sex (M: *n*, %)36562.39347.417666.29677.4BMI (kg/m^2^: mean, sd)26.14.326.04.626.24.026.04.2With COPD (*n*, %)41170.110654.120075.210584.7Current smoker (*n*, %)275*46.9*11156.611543.24939.5Pack years (mean, sd)41.124.032.818.844.124.847.626.2Emphysema \> 10%LAA (*n*, %)26344.96633.713048.96754.0Bone attenuation (HU: mean, sd)158.446.5174.943.4154.042.6141.551.2≥ 1 prevalent VF (*n*, %)12321.02010.26122.94233.9Incident VF within 1 year (*n*, %)579.7147.1228.32116.9Incident VF within 3 years (*n*, %)13723.44020.46022.63729.8Baseline characteristics for all subjects and by Agatston score group. Zero 0 Agatston units (AU); medium 1--400 AU; high \> 400 AU*BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *%LAA* % low attenuation area, *HU* Hounsfield units, *VF* vertebral fractureFig. 1Proportion of patients with a prevalent VF (left panel) or 1- or 3-year incident VF (right panel) stratified by Agatston score. AU Agatston units, VF vertebral fracture

Association between prevalent VFs and baseline Agatston score {#Sec9}
-------------------------------------------------------------

Of the subjects with one or more prevalent VF, 20 (16%) had zero Agatston score, 61 (50%) had medium Agatston score, and 42 (34%) had high Agatston score. In subjects without prevalent VFs, these numbers were 176 (38%), 205 (44%), and 82 (18%) respectively (Supplemental Figure [1](#MOESM1){ref-type="media"}).

In univariate models, subjects with prevalent VFs had higher odds of a medium (OR 2.62 \[1.52--4.51\]) or high Agatston score (OR 4.51 \[2.49--8.16\]) compared to subjects without VFs (Table [2](#Tab2){ref-type="table"}). In multivariate models, subjects with prevalent VFs had higher odds of having a medium (1.83 \[95% CI 1.009--3.304\]) or high (OR = 3.06 \[1.450--6.473\]) Agatston score compared to subjects without VFs. After additional adjustment for BA, subjects with prevalent VFs still had higher odds of high (OR = 2.37 \[1.06--5.31\]), but not of medium Agatston score (OR = 1.56 \[0.84--2.90\]).Table 2Association between prevalent VFs and Agatston scoreUnivariateMultivariate, without BAMultivariate, with BAOR95% CIOR95% CIOR95% CIMedium Agatston scoreAge (per + 8 years)*2.16\[1.750--2.654\]1.84\[1.446--2.332\]1.67\[1.296--2.150\]Sex (M vs F)2.17\[1.484--3.162\]1.79\[1.183--2.703\]1.85\[1.220--2.808\]*BMI (per + 4 kg/m^2^)1.05\[0.879--1.243\]----Current smoker (vs former)*0.58\[0.402--0.846\]*----Pack years (per + 24 pack years)*1.95\[1.502--2.537\]1.37\[1.041--1.791\]1.39\[1.060--1.828\]*COPD (vs no COPD)*2.57\[1.733--3.821\]*1.26\[0.781--2.030\]1.27\[0.788--2.062\]BA (per − 46 HU)*1.68\[1.367--2.072\]*--*1.30\[1.024--1.664\]*≥ 1 prevalent VF (vs none)*2.62\[1.520--4.510\]1.83\[1.009--3.304\]*1.57\[0.853--2.883\]Emphysema (vs "no emphysema")*1.88\[1.286--2.757\]*----High Agatston scoreAge (per + 8 years)*4.81\[3.373--6.854\]3.97\[2.718--5.809\]3.69\[2.512--5.412\]*Sex (M vs F)*3.80\[2.290--6.297\]2.75\[1.473--5.118\]3.08\[1.616--5.885\]*BMI (per + 4 kg/m^2^)1.01\[0.828--1.241\]----Current smoker (vs former)0.50\[0.317--0.791\]----Pack years (per + 24 pack years)*2.17\[1.610--2.914\]1.60\[1.124--2.272\]1.57\[1.099--2.237\]*COPD (vs no COPD)*4.69\[2.670--8.244\]*1.39\[0.665--2.916\]1.38\[0.657--2.886\]BA (per − 46 HU)*2.12\[1.630--2.751\]1.43\[1.031--1.971\]*≥ 1 prevalent VF (vs none)*4.51\[2.490--8.158\]3.06\[1.450--6.473\]2.47\[1.128--5.403\]*Emphysema (vs "no emphysema")*2.32\[1.460--3.671\]*----Significant ORs are in italic format. For continuous variables, ORs are given per standard deviation of the total population. Multivariate: confounders included according to \> 5% rule (age, sex, and presence of COPD were included in all models). Reference group is the zero Agatston score group*OR* odds ratio, *95% CI* 95% confidence interval, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *BA* bone attenuation, *HU* Hounsfield units, *VF* vertebral fracture, *%LAA* % low attenuation area

In univariate models, odds of medium or high Agatston score for subjects with emphysema (\> 10%LAA) were 1.88 \[1.29--2.76\], but this was not significant after adjustment for age and sex.

Association between baseline Agatston score and prevalent VFs {#Sec10}
-------------------------------------------------------------

Characteristics of subjects with (*n* = 123) or without (*n* = 463) prevalent VFs are given in Table [3](#Tab3){ref-type="table"}. In univariate models, subjects with medium (2.62 \[1.52--4.51\]) or high Agatston score (4.51 \[2.49--8.16\]) had higher odds of having a prevalent VF compared to subjects with a zero Agatston score. In multivariate models, subjects with medium (OR = 1.91 \[1.07--3.40\]) or high Agatston score (OR = 2.71 \[1.40--5.26\]) had significantly increased odds of having a prevalent VF compared to subjects with a zero score. After additional adjustment for BA, subjects with high but not medium Agatston score had significantly higher odds of prevalent VFs than subjects with a zero score (OR = 2.03 \[1.01--4.08\] and OR = 1.60 \[0.88--2.92\] respectively; Table [3](#Tab3){ref-type="table"}).Table 3Association between Agatston score and prevalent VFsWithout VFWith VFUnivariateMultivariate, without BAMultivariate, with BA*n* = 463*n* = 123OR95% CIOR95% CIOR95% CIAge (years: mean, sd)59.18.362.67.7Per + 8 years*1.55\[1.255--1.907\]*1.24\[0.983--1.572\]0.97\[0.743--1.255\]Sex (M: *n*, %)26757.79879.7M vs F*2.88\[1.787--4.633\]2.28\[1.394--3.741\]2.87\[1.707--4.812\]*BMI (kg/m^2^)26.14.326.04.0Per + 4 kg/m^2^0.97\[0.803--1.169\]----Current smoker (*n*, %)22448.45141.5Vs former smoker0.76\[0.505--1.130\]----Pack years (mean, *n*)39.623.546.625.3Per + 24 pack years*1.30\[1.080--1.555\]*1.08\[0.886--1.320\]1.09\[0.881--1.351\]COPD (*n*, %)31768.59476.4Vs no COPD1.49\[0.942--2.365\]----BA (HU: mean, sd)165.845.2130.240.3Per − 46 HU*2.60\[2.008--3.375\]*--*2.54\[1.899--3.400\]*Emphysema (\> 10%LAA: *n*, %)20143.46250.4Vs "no emphysema"1.32\[0.890--1.973\]----Zero Agatston group (*n*, %)17638.02016.3----Medium Agatston group (*n*, %)20544.36149.6Vs zero Agatston score*2.62\[1.520--4.510\]1.91\[1.069--3.396\]*1.60\[0.876--2.915\]High Agatston group (*n*, %)8217.74234.1Vs zero Agatston score*4.51\[2.490--8.159\]2.71\[1.389--5.264\]2.03\[1.013--4.080\]*Significant ORs are in italic format. For continuous variables, ORs are given per standard deviation of the total population. Multivariate: confounders included according to \> 5% rule (age, sex, and having COPD included in all models)*VF* vertebral fracture, *OR* odds ratio, *95% CI* 95% confidence interval, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *BA* bone attenuation, *HU* Hounsfield units, *%LAA* % low attenuation area

Association between baseline Agatston score and incident VFs within 1 and 3 years {#Sec11}
---------------------------------------------------------------------------------

There were 57 subjects (9.7%) with incident VFs within 1 year and 137 (23.4%) within 3 years after baseline (Table [1](#Tab1){ref-type="table"}). Of the subjects with one or more incident VFs within 3 years, 40 (29.2%) had zero Agatston score, 60 (43.8%) had medium Agatston score, and 37 (27%) had high Agatston score (Table [4](#Tab4){ref-type="table"}). In subjects without incident VFs, these numbers were 156 (35%), 206 (46%), and 87 (19%) respectively (Supplemental Figure [2](#MOESM1){ref-type="media"}).Table 4Association between Agatston score group and incident VFsUnivariateMultivariate, without BAMultivariate, with BAHR95% CIHR95% CIHR95% CIOne-year incidenceAge (per + 8 years)*1.49\[1.129--1.954\]*1.25\[0.897--1.737\]1.17\[0.827--1.645\]Sex (M vs F)*2.05\[1.107--3.815\]*1.43\[0.738--2.749\]1.46\[0.757--2.831\]BMI (per + 4 kg/m^2^)0.84\[0.652--1.082\]0.90\[0.690--1.177\]0.96\[0.726--1.269\]Current smoker (vs former)0.95\[0.561--1.592\]1.28\[0.716--2.296\]1.32\[0.736--2.367\]Pack years (per + 24 pack years)1.21\[0.977--1.489\]1.07\[0.825--1.379\]1.07\[0.827--1.382\]COPD (vs no COPD)1.78\[0.925--3.446\]0.86\[0.352--2.077\]0.87\[0.357--2.106\]Emphysema (\> 10%LAA, vs ≤ 10%LAA)*2.11\[1.234--3.620\]*1.89\[0.936--3.805\]1.85\[0.913--3.740\]BA (per − 46 HU)*1.79\[1.337--2.395\]*1.27\[0.910--1.785\]≥ 1 prevalent VF (vs none)*3.93\[2.338--6.607\]3.19\[1.830--5.553\]2.75\[1.523--4.970\]*Medium Agatston score (vs zero)1.16\[0.595--2.272\]0.69\[0.335--1.425\]0.67\[0.323--1.373\]High Agatston score (vs zero)*2.37\[1.206--4.662\]*1.05\[0.481--2.279\]0.97\[0.444--2.130\]Three-year incidenceAge (per + 8 years)*1.24\[1.046--1.466\]*1.12\[0.916--1.378\]1.05\[0.847--1.297\]Sex (M vs F)*1.70\[1.161--2.484\]*1.33\[0.890--1.998\]1.37\[0.915--2.060\]BMI (per + 4 kg/m^2^)0.92\[0.784--1.080\]0.97\[0.817--1.152\]1.03\[0.859--1.226\]Current smoker (vs former)1.11\[0.798--1.558\]1.37\[0.939--2.006\]1.40\[0.956--2.039\]Pack years (per + 24 pack years)1.09\[0.939--1.274\]0.97\[0.811--1.165\]0.98\[0.816--1.173\]COPD (vs no COPD)1.40\[0.940--2.075\]1.15\[0.686--1.931\]1.16\[0.690--1.939\]Emphysema (\> 10%LAA, vs ≤ 10%LAA)0.74\[0.526--1.028\]1.24\[0.812--1.891\]1.22\[0.796--1.862\]BA (per − 46 HU)1.56\[1.302--1.878\]*1.29\[1.034--1.598\]*≥ 1 prevalent VF (vs none)*3.50\[2.503--4.892\]3.30\[2.307--4.713\]2.84\[1.944--4.152\]*Medium Agatston score (vs zero)1.11\[0.741--1.649\]0.76\[0.494--1.180\]0.73\[0.472--1.129\]High Agatston score (vs zero)1.46\[0.935--2.287\]0.80\[0.479--1.335\]0.74\[0.441--1.241\]Significant HRs are in italic format. For continuous variables, HRs are given per standard deviation of the total population. Multivariate: confounders included according to \> 5% rule (age, sex, and having COPD included in all models)*VF* vertebral fracture, *HR* hazard ratio, *95% CI* 95% confidence interval, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *%LAA* % low attenuation area, *BA* bone attenuation, *HU* Hounsfield units

In univariate models, subjects with high prevalent Agatston score had a significantly increased risk of 1-year VF incidence (HR = 2.37 \[1.21--4.66\]), but of the higher 3-year incidence risk was not significant (HR = 1.46 \[0.94--2.29\]). In multivariate models, subjects with medium or high prevalent Agatston score had no significantly increased VFs risk and this was mainly due to the effect of adding prevalent VFs, age, and BA to the model. However, subjects with a prevalent VF and, in case of 3-year incidence, also subjects with lower BA had increased risk of VF incidence.

When the number of incident VFs (0, 1, or ≥ 2) was taken as outcome measure, there were significant univariate associations between subjects with high Agatston score and ≥ 2 incident VFs (1-year OR = 9.72 \[2.11--44.72\]; 3-year OR = 3.79 \[1.64--8.73\]), but in multivariate models, this was no longer significant.

Discussion {#Sec12}
==========

In this study, we found an association between prevalent VFs and high Agatston score on chest CT scans in (former) smokers with and without COPD. Associations between Agatston score and incident VFs were not significant in multivariate models. The clinical consequence is that when chest CT scans are performed in (former) smokers to evaluate pulmonary function, supplementary evaluation of the presence of VFs and the degree of CAC gives information on risk factors for other diseases for which additional treatment can be considered.

In line with an earlier review \[[@CR9]\], we found significant independent associations between BA, prevalent VFs, and high Agatston score. An association between VFs and Agatston score is consistent with the reported correlation of FRAX-estimated risk of hip fracture or major osteoporotic fracture with CAC score \[[@CR38]\]. Some linking mechanisms have been proposed, such as an association between micro- and macro-vessel damage and altered microarchitectural indices in the radius \[[@CR39]\], or between decreased vascular flow in the lower extremities and increased rate of bone loss at the hip and calcaneus in older women \[[@CR40]\]. We suggest that the association between CAC and VFs in part may be explained by the shared risk factor of smoking.

Vascular calcifications in the aorta are commonly seen in patients with osteoporosis, and both increase with aging and with renal disease. Possibly related to renal disease, vascular smooth muscle cells can secrete inhibitors of wnt-signalling that lower bone formation rates. It has been postulated that low bone formation rates fail to buffer high mineral loads and could thus predispose to vascular calcification.

Current smokers had lower odds of having a medium (Table [2](#Tab2){ref-type="table"}; OR = 0.58 \[0.40--0.85\]) or a high (OR = 0.50 \[0.32--0.79\]) Agatston score compared to former smokers. This may seem unexpected, but in this population, former smokers were significantly older (62.3 ± 7.1 vs 57.0 ± 8.7), more often had COPD (84.9% vs 53.5%), and had lower BA (154.0 ± 45.3 vs 163.2 ± 47.4) as compared to current smokers.

There were relatively fewer women (*n* = 221) than men (*n* = 365) included in this study. A lower percentage of women had a prevalent VF than men in this subcohort (11.3% vs 26.8%), as reported in our previous study (14.1% vs 24.5%) \[[@CR8]\]. In addition, women less often had medium (40.7%) or high Agatston score (12.7%) than men (48.2% and 26.3% resp.), resulting in very few women with VF and high Agatston score (*n* = 6 (3%)).

When analyses regarding the associations between Agatston score and VFs were performed for men and women separately, the associations for men were similar as presented. However, the associations in women were not significant, not surprisingly given the small number of women in the high risk group. However, it is possible that the women included in this study do not represent the female COPD and smoker population (selection bias) and/or that the association between CAC and VFs is different in men and women.

The literature has been contradictory about the association between emphysema and CACS; some studies found an association between emphysema and CAC \[[@CR12], [@CR13]\], while others did not \[[@CR14]--[@CR16]\]. Although we found a univariate association between emphysema and medium or high Agatston score (Table [2](#Tab2){ref-type="table"}), this association was not significant after adjustment for age and sex.

Although there was a significant univariate association between high Agatston score and 1-year incidence, and between high Agatston score and ≥ 2 incident VFs within 1 and 3 years, we did not find any significant multivariate associations between Agatston score and incident VFs after adjusting for age, sex, BA, and prevalent VFs.

A recent meta-analysis examined data from prospective cohort studies of aortic calcification and fractures \[[@CR41]\]. Although not all individual studies found significant results, it was reported that subjects in the high aortic calcification category had increased fracture risk compared to subjects in the zero category. However, when types of fractures were specified, Wei et al. reported that the association with incident VFs was not significant, consistent with our findings. They also reported a significant association with incident hip fractures, for which we do not have data. In our results, prevalent VFs (associated with high Agatston score (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"})) and to a lesser extent baseline BA were significantly associated with incident VFs, also consistent with previous findings \[[@CR37]\]. The significant association between high Agatston score and incident VFs disappeared after adjustment. The point estimate shifted towards one which suggests that there is no association between Agatston score measured at baseline and the risk of incident VFs within 1 year. Moreover, there was also no association with incident VFs over 3 years.

In multivariate models, we found an association between prevalent VFs and high Agatston score. Therefore, we suggest all current and former smokers diagnosed with either osteoporosis; a prevalent VF or coronary artery calcification should be evaluated for the osteoporosis or coronary artery disease respectively. Given the relative simplicity of measuring the Agatston score on the chest CTs, we suggest this measurement should be routinely performed and reported and high levels should trigger further assessments including of bone attenuation and coronary artery disease.

There are several limitations in this study.

First, there is a chance of a selection bias due to inclusion of subjects for the ECLIPSE study and selection of subjects from the ECLIPSE study. For the ECLIPSE study, subjects were recruited from outpatient clinics, and subjects with mild COPD (GOLD stage I) or who were using oral GC at baseline were excluded. In addition, only non-Hispanic whites were included. From the ECLIPSE study, only subjects with availability of the complete VF assessment \[[@CR8]\] and Agatston score evaluation \[[@CR15]\] were included for this study. Subjects included (*n* = 586) were somewhat younger, had lower BMI, less often had COPD, more often were current smokers, and less often had emphysema (\> 10%LAA) compared to all ECLIPSE subjects (*n* = 2298). For characteristics of included subjects (*n* = 586) and total ECLIPSE population (*n* = 2298), see e-Table [1](#MOESM2){ref-type="media"}, online supplement.

VF data were only available from vertebrae T~1~--L~1~, so information on prevalent or incident VFs in L~2~--L~5~ is lacking. Also, due to the design of the ECLIPSE study information on other risk factors for fractures, such as the history of falls and fractures, family history of other fractures (including hip fracture), presence of rheumatoid arthritis, or other metabolic disorders were not available and could not be used for adjustment of models for incident VFs. Lastly, Agatston score was only measured at baseline and follow-up data concerning Agatston score are not available.

Conclusion {#Sec13}
==========

In this study of current and former smokers from the ECLIPSE study, we have shown a significant association between prevalent VFs and Agatston score, underlining the concept of multiple comorbidities in this patient group. This indicates that in clinical practice, (former) smokers, who are assessed for and diagnosed with either VF or CAC, should be screened for the other. Since VFs and Agatston score can be diagnosed in CT scans made for pulmonary evaluation, we also recommend opportunistic evaluation of these scans for VFs and CACs as potentially important comorbidities, each of which is amenable to effective interventions.
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